全文获取类型
收费全文 | 13339篇 |
免费 | 986篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 121篇 |
儿科学 | 495篇 |
妇产科学 | 409篇 |
基础医学 | 2053篇 |
口腔科学 | 369篇 |
临床医学 | 1621篇 |
内科学 | 2643篇 |
皮肤病学 | 344篇 |
神经病学 | 1296篇 |
特种医学 | 334篇 |
外科学 | 1031篇 |
综合类 | 102篇 |
一般理论 | 4篇 |
预防医学 | 1153篇 |
眼科学 | 197篇 |
药学 | 876篇 |
中国医学 | 15篇 |
肿瘤学 | 1292篇 |
出版年
2023年 | 95篇 |
2022年 | 53篇 |
2021年 | 260篇 |
2020年 | 283篇 |
2019年 | 337篇 |
2018年 | 332篇 |
2017年 | 296篇 |
2016年 | 345篇 |
2015年 | 443篇 |
2014年 | 534篇 |
2013年 | 739篇 |
2012年 | 1100篇 |
2011年 | 1084篇 |
2010年 | 639篇 |
2009年 | 551篇 |
2008年 | 904篇 |
2007年 | 934篇 |
2006年 | 905篇 |
2005年 | 865篇 |
2004年 | 816篇 |
2003年 | 749篇 |
2002年 | 680篇 |
2001年 | 134篇 |
2000年 | 80篇 |
1999年 | 113篇 |
1998年 | 127篇 |
1997年 | 107篇 |
1996年 | 71篇 |
1995年 | 79篇 |
1994年 | 68篇 |
1993年 | 65篇 |
1992年 | 49篇 |
1991年 | 51篇 |
1990年 | 37篇 |
1989年 | 38篇 |
1988年 | 46篇 |
1987年 | 31篇 |
1986年 | 24篇 |
1985年 | 28篇 |
1984年 | 38篇 |
1983年 | 30篇 |
1982年 | 21篇 |
1981年 | 17篇 |
1980年 | 19篇 |
1979年 | 11篇 |
1978年 | 17篇 |
1977年 | 24篇 |
1975年 | 12篇 |
1974年 | 14篇 |
1967年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Tellapragada Chaitanya Ydsten Karin Andersson Ternhag Anders Giske Christian G. 《European journal of clinical microbiology & infectious diseases》2022,41(7):1093-1098
European Journal of Clinical Microbiology & Infectious Diseases - We investigated the concordance between the Unyvero Hospitalized Pneumonia (HPN) application and quantitative culture for... 相似文献
3.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
4.
Joshua P. Entrop Caroline E. Weibull Karin E. Smedby Lasse H. Jakobsen Andreas K. Øvlisen Daniel Molin Ingrid Glimelius Anna Marklund Harald Holte Alexander Fosså Knut B. Smeland Tarec C. El-Galaly Sandra Eloranta 《International journal of cancer. Journal international du cancer》2023,153(4):723-731
Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18-40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995-2018, who were linked to national medical birth registers. Cox regression adjusted for stage, performance status, year, and age at diagnosis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) contrasting time to first childbirth by treatment groups (ABVD, 2-4 BEACOPP, 6-8 BEACOPP) up to 10 years after diagnosis. Overall, 74.8% of patients were treated with ABVD, 3.1% with 2-4 BEACOPP and 11.2% with 6-8 BEACOPP. Adjusted HRs comparing childbirth rates in individuals treated with 6-8 BEACOPP, and 2-4 BEACOPP to ABVD were 0.53 (CI: 0.36-0.77) and 0.33 (CI: 0.12-0.91) for males, and 0.91 (CI: 0.61-1.34) and 0.38 (CI: 0.12-1.21) for females. Cumulative incidence of childbirths after 10 years was 19.8% (CI: 14.5%-27.0%) for males and 34.3% (CI: 25.8%-45.6%) for females treated with 6-8 BEACOPP. Proportions of children born after assisted reproductive technique (ART) treatments were 77.4% (CI: 60.2-88.6%) for males following 6-8 BEACOPP, and <11% for females. Among ABVD treated patients the corresponding proportions were 12.2% (CI: 8.5%-17.3%) and 10.6% (CI: 7.4%-14.9%). BEACOPP treatment is associated with decreased childbirth rates compared to ABVD in male, but not female, cHL patients, despite widespread access to ART in the Nordics. 相似文献
5.
6.
7.
8.
9.
10.